drugset / Trial / NCT07222917

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

NCT07222917

Phase 2 Recruiting 218 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

Timeline

Start
2025-12-05
Primary completion
2027-05-24
Completion
2027-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule
Background Baxdrostat Small molecule